Pamlico BioPharma

Pamlico BioPharma


Pamlico Biopharma, Inc. develops fully human monoclonal antibodies (hmAbs) for the diagnosis and treatment of infectious diseases and cancer. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and Emory University to rapidly characterize and isolate fully-human monoclonal antibodies that arise from the body’s natural immune response following vaccination or infection. Pamlico has successfully isolated high affinity antibodies to a wide range of human pathogens, including influenza, anthrax, rabies, varicella zoster, Japanese encephalitis, and all 24 vaccine serotypes of Streptococcus pneumoniae. Pamlico’s lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN) and is in IND-directed activities for a mAb cocktail (PneumoMab™) and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of pneumococcal pneumonia cases annually. The company’s discovery efforts currently include development of antibodies for Hepatitis B, tuberculosis, human pampillomavirus, Yellow Fever, and cancer.

Learn more at

Request more information about Pamlico

  • Antibiotics
  • Monoclonal Antibodies
  • Preclinical